Zealand Pharma Lands Novel Eli Lilly R&D Deal In Diabetes And Obesity
This article was originally published in The Pink Sheet Daily
Executive Summary
Zealand Pharma has landed another major partnership, this time with Lilly to help develop what the Danish biotech hopes will be a novel, best-in-class treatment for obesity and type 2 diabetes. The process will take years but could lead to other innovative drug deals with the U.S. drug maker.
You may also be interested in...
Zealand’s New CEO Emphasizes Her Market Access, Pricing Experience
Recently appointed chief exec Britt Meelby Jensen said in an interview that she is poised to lead the developer of innovative peptide drugs into its next phase of operation – getting to market.
GLP1 Diabetes Showdown Nears As Lyxumia Gets Green Light In Europe
The EU's Committee for Medicinal Products for Human Use has recommended two Sanofi products - the diabetes therapy Lyxumia and the colorectal cancer drug Zaltrap – while also backing the first vaccine in Europe for meningitis B, Novartis' Bexsero.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.